Almirall at a Glance
At Almirall, an international pharmaceutical company based on innovation and committed to health, with its headquarters in Barcelona (Spain), we research, develop, produce and market proprietary R&D medicines and those under license in order to improve people's health and wellbeing.
Our medicines are present in over 70 countries with a direct presence in Europe and Latin America.
A leading international pharmaceutical company in R&D with its headquarters in Spain (# 1 Spanish pharma, # 1 dermatology company in Germany and # 8 across Europe)
- Founded in 1943.
- Listed on the stock exchange on 20 June 2007.
- Over 3,000 employees around the world.
- Direct presence in 12 countries.
- Marketing of proprietary products in over 70 countries.
- Sales of € 925,5 MM (+2.5%) and an EBITDA of € 243,9 MM (+6%) in 2009.
International expanding business
- Main latest milestones:
- Success in achieving approval of own R&D products in the USA, the United Kingdom and Japan over the last 20 years.
- Acquisition of Hermal, the European prescription dermatology business of Reckitt Benckiser. (2007)
- Acquisition of a portfolio of 8 products from Shire plc. (2007)
- Opening of new affiliates (United Kingdom + Ireland, Austria, Poland and Switzerland). (2008)
- Two license-in deals (sitagliptin and amlodipine+atorvastatin). (2008)
- International earnings represent 42% of the total in 2009 and continue to grow.
- Two license-in deals (linaclotide and silodosin). (2009)
Relevant strategic agreements
- J&J, Forest (USA)
- Dainippon Sumitomo (Japan)
- Gedeon Richter (Eastern Europe)
- Nycomed (Russia and CIS, Scandinavia)
- Ironwood (Europe)
- Pfizer, MSD, GSK, Wyeth, Recordati (Spain)
Diversified and patented product portfolio
- Promotional approach focusing on key brands.
Key areas in R&D
- Respiratory diseases (asthma and COPD), auto-immune system (rheumatoid arthritis, multiple sclerosis), psoriasis and other dermatology indications.
- Finding the balance between risk and profitability
- Basis for internationalisation
- R&D focused on aclidinium bromide (aclidinium bromide showed to improve lung function and was well tolerated in the phase III trials with a desirable risk benefit profile. New clinical trials in 2009).
Experienced management team with a good proven track record
- Almirall has the capacity to grow by means of its own R&D, third party licensing (“licenses in”) and mergers and acquisitions.
| ||||
Share Evolution
Latest Press Releases
| 30/07/10 8:30 a.m. First Half 2010 in line with guidance, strong R&D catalysts expected in second half |
| 28/07/10 8:30 a.m. Sativex® receives regulatory authorisation in Spain |
